Head-to-head evidence
amiselimod vs ozanimod
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Ulcerative Colitis
Shared mechanism: S1P receptor · full Ulcerative Colitis pipeline
amiselimod
Developed by Bausch Health under a licence from Mitsubishi Tanabe Pharma
NCT04857112 · Phase 2 · completed
This trial randomly assigned 322 people with ulcerative colitis to one of two amiselimod doses or placebo, with participants and investigators unaware of assignment. The primary measure was change in the modified Mayo Score, which combines the appearance of the bowel lining at endoscopy with clinical disease activity. Scores fell by 2.3 points on amiselimod against 1.6 points on placebo (p=0.002).
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
ozanimod · Zeposia
Marketed by Bristol-Myers Squibb
NCT02435992 · Phase 3 · completed
Randomized, quadruple-blinded, placebo-controlled, large adequately powered Phase 3 trial (n=1012) with a hard clinical/endoscopic remission endpoint that achieved statistical significance in the favorable direction at both induction and maintenance timepoints, satisfying the 'strong' definition.
Next expected readout: July 2032 · NCT05076175 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: amiselimod's landscape · ozanimod's landscape